Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes

Netherlands Journal of Medicine

Volumn 64, Issue 8, 2006, Pages 269-279

  de Galan, B E ^a   Schouwenberg, B J J W ^a   Tack, C J ^a   Smits, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Glucose counterregulation; Hypoglycaemia unawareness; Insulin treatment

Indexed keywords

GLUCAGON; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE;

ADULT; BLOOD GLUCOSE MONITORING; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT EDUCATION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; RISK FACTORS;

EID: 33749056206     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Lawrence RD. Insulin hypoglycaemia. Changes in nervous manifestations. Lancet 1941;ii:602-4.
2. Gross TM, Mastrototaro JJ, Fredrickson LP. Detection of unseen hypoglycemia using continuous glucose monitoring. Diabetologia 2003;43(suppl 1):A5-19.
3. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression oflong-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
5. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*. Diabetologia 2002;45:937-48.
6. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion, J Clin Endocrinol Metab 1983;56:1294-300.
7. Porksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia 2002;45:3-20.
8. Heller SR. Diabetic hypoglycaemia. Baillieres Best Pract Res Clin Endocrinol Metab 1999;13:279-94.
9. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450-9.
10. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987;79:777-81.
11. Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991;260:E67-74.
12. Unger RH. The Berson memorial lecture. Insulin-glucagon relationships in the defense against hypoglycemia. Diabetes 1983;32:575-83.
13. Ter Braak E, Appelman A, Erkelens D, van Haeften T. Glibenclamide decreases glucagon release during mild hypoglycaemia. Diabetologia 1998;41(Suppl 1):A68,
14. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 2002;51:958-65.
15. Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med 1988;318:1487-92.
16. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991;40:223-6.
17. Davis MR, Shamoon H. Counterregulatory adaptation to recurrent hypoglycemia in normal humans. J Clin Endocrinol Metab 1991;73:995-1001.
18. Davis SN, Shavers C, Mosqueda Garcia R, Costa F. Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 1997;48:1328-35.
19. Davis SN, Fowler S, Costa F. Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes. Diabetes 2000;49:65-72.
20. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994;78:1341-8.
21. Mei Q, Mundinger TO, Lernmark A, Taborsky GJ Jr. Early, selective, and marked loss of sympathetic nerves from the islets of BioBreeder diabetic rats. Diabetes 2002;51:2997-3002.
22. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988;37:901-7.
23. Dagogo Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993;91:819-28.
24. De Galan BE, Tack CJ, Willemsen JJ, Sweep CG, Smits P, Lenders JW. Plasma metanephrine levels are decreased in type 1 diabetic patients with a severely impaired epinephrine response to hypoglycemia, indicating reduced adrenomedullary stores of epinephrine. J Clin Endocrinol Metab 2004;89:2057-61.
25. White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983;308:485-91.
26. Bolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes 1984;33:732-7.
27. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703.
28. Trovik TS, Jaeger R, Jorde R, Sager G. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994;38:427-32.
29. Korytkowski MT, Mokan M, Veneman TF, Mitrakou A, Cryer PE, Gerich JE. Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 1998;21:1939-43.
30. Enoksson S, Caprio SK, Rife F, Shulman GI, Tamborlane WV, Sherwin RS. Defective activation of skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia. J Clin Endocrinol Metab 2003;88:1503-11
31. Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 2001;281:E1115-21.
32. Davis SN, Mann S, Galassetti P, et al. Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 2000;49:1897-903.
33. Davis SN, Tate D. Effects of morning hypoglycemia on neuroendocrine and metabolic responses to subsequent afternoon hypoglycemia in normal man. J Clin Endocrinol Metab 2001;86:2043-50.
34. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 1993;42:1233-7.
35. Ovalle F, Fanelli CG, Paramore DS, Hershey T, Craft S, Cryer PE. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998;47:1472-9.
36. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994;43:1379-89.
37. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. The adrenal medullary response to hypoglycemia in patients with orthostatic hypotension. J Clin Endocrinol Metab 1980;51:1401-6.
38. Hoeldtke RD, Boden G, Shuman CR, Owen OE. Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med 1982;96:459-62.
39. Bottini P, Boschetti E, Pampanelli S, et al. Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect. Diabetes 1997;46:814-23.
40. Hepburn DA, Patrick AW, Eadington DW, Ewing DJ, Frier BM. Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 1990;7:711-7.
41. Stephenson JM, Kempler P, Perin PC, Fuller JH. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1372-6.
42. de Galan BE, Hoekstra JB. Glucose counterregulation in Type 2 diabetes mellitus. Diabet Med 2001;18:519-27.
43. Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 1994;93:2562-71.
44. Levy CJ, Kinsley BT, Bajaj M, Simonson DC. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 1998;21:1330-8.
45. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994;43:403-10.
46. Spyer G, Hattersley AT, MacDonald IA, Amiel S, MacLeod KM. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 2000;356:1970-4.
47. Korzon Burakowska A, Hopkins D, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998;21:283-90.
48. Ortiz Alonso FJ, Herman WH, Zobel DL, Perry TJ, Smith MJ, Halter JB. Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM. Diabetes 1991;40:1194-202.
49. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80.
50. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724-33.
51. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-21.
52. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Recall of severe hypoglycaemic episodes and course of hypoglycaemia awareness in insulin-treated Type 2 diabetes in one year follow-up. Diabetologia 2003;46:A304.
53. Davis SN, Shavers C, Costa F, Mosqueda Garcia R. Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. J Clin Invest 1996;98:680-91.
54. McGregor VP, Banarer S, Cryer PE. Elevated enclogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab 2002;282:E770-7.
55. Davis SN, Shavers C, Davis B, Costa F. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997;100:429-38.
56. Raju B, McGregor VP, Cryer PE. Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Diabetes 2003;52:2083-9.
57. Galassetti P, Mann S, Tate D, et al. Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 2001;280:E908-17.
58. McGregor VP, Greiwe JS, Banarer S, Cryer PE. Limited impact of vigorous exercise on defenses against hypoglycemia: relevance to hypoglycemia-associated autonomic failure. Diabetes 2002;51:1485-92.
59. McCall AL, Fixman LB, Fleming N, Tornheim K, Chick W, Ruderman NB. Chronic hypoglycemia increases brain glucose transport. Am J Physiol 1986;251:E442-7.
60. Uehara Y, Nipper V, McCall AL. Chronic insulin hypoglycemia induces GLUT-3 protein in rat brain neurons. Am J Physiol 1997;272:E716-9.
61. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 1995;44:1399-404.
62. Boyle PJ, Nagy RJ, O'Connor AM, Kempers SF, Yeo RA, Qualls C. Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc Natl Acad Sci U S A 1994;91:9352-6.
63. Boyle PJ, Kempers SF, O'Connor AM, Nagy RJ. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus [see comments]. N Engl J Med 1995;333:1726-31.
64. Benzo CA. Minireview. The hypothalamus and blood glucose regulation. Life Sci 1983;32:2509-15.
65. Biggers DW, Myers SR, Neal D, et al. Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 1989;38:7-16.
66. Frizzell RT, Jones EM, Davis SN, et al. Counterregulation during hypoglycemia is directed by widespread brain regions. Diabetes 1993;42:1253-61.
67. McCrimmon RJ, Jacob RJ, Fan X, McNay EC, Sherwin RS. Effects of recurrent antecedent hypoglycaemia and chronic hyperglycaemia on brainstem extra-cellular glucose concentrations during acute hypoglycaemia in conscious diabetic BB rats. Diabetologia 2003;46:1658-61.
68. McNay EC, Sherwin RS, Effect of recurrent hypoglycemia on spatial cognition and cognitive metabolism in normal and diabetic rats. Diabetes 2004;53:418-25.
69. Segel SA, Fanelli CG, Dence CS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001;50:1911-7.
70. 11C-3-O-methyl-D-glucose PET study. Diabetologia 2005; 49:2090-9.
71. Fagius J, Berne C. Changes of sympathetic nerve activity induced by 2-deoxy-D- glucose infusion in humans. Am J Physiol 1989;256:E714-20.
72. Amiel SA, Archibald HR, Chusney C, Williams AJ, Gale EA. Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin Sci Colch 1991;81:189-94.
73. Maran A, Cranston I, Lomas J, Macdonald I, Amiel SA. Protection by lactate of cerebral function during hypoglycaemia [see comments]. Lancet 1994;343:16-20.
74. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 1994;43:1311-7.
75. Bischof MG, Mlynarik V, Brehm A, et al. Brain energy metabolism during hypoglycaemia in healthy and type 1 diabetic subjects. Diabetologia 2004;47:648-51.
76. De Galan BE, Van der Graaf M, Klomp D, Parkes LM, Heerschap A, Tack CJ. Feasibility study on the use of MRS to investigate human brain metabolism in vivo during hypoglycemia. Diabetes 2005;54:A155.
77. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*. Diabetologia 2002;45:937-48.
78. Tattersall RB, Gill GV. Unexplained deaths oftype 1 diabetic patients. Diabet Med 1991;8:49-58.
79. Campbell I. Dead in Bed Syndrome - A New Manifestation of Nocturnal Hypoglycemia. Diabet Med 1991;8:3-4.
80. Robinson RT, Harris ND, Ireland RH, MacDonald IA, Heller SR. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with Type 1 diabetes. Diabetologia 2004;47:312-5.
81. Lindstrom T, Jorfeldt L, Tegler L, Arnqvist HJ. Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med 1992;9:536-41.
82. Agardh CD, Rosen I, Ryding E. Persistent vegetative state with high cerebral blood flow following profound hypoglycemia. Ann Neurol 1983;14:482-6.
83. Chalmers J, Risk MT, Kean DM, Grant R, Ashworth B, Campbell IW. Severe amnesia after hypoglycemia. Clinical, psychometric, and magnetic resonance imaging correlations. Diabetes Care 1991;14:922-5.
84. Perros P, Sellar RJ, Frier BM. Chronic pontine dysfunction following insulin-induced hypoglycemia in an IDDM patient. Diabetes Care 1994;17:725-7.
85. Casey E, Evans A, Krentz A, Watkins P, Hopkins D. Central Pontine myelinolysis. An unusual complication of diabetes. Diabetes Care 1999;22:998-1000.
86. Musen G, Lyoo IK, Sparks CR, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry, Diabetes 2006;55:326-33.
87. Langan SJ, Deary IJ, Hepburn DA, Frier BM. Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. Diabetologia 1991;34:337-44.
88. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-8.
89. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996;124:379-88.
90. Austin EJ, Deary IJ. Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis ofthe Diabetes Control and Complications Trial data. Diabetes Care 1999;22:1273-7,
91. Ferguson SC, Blane A, Perros P, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 2003;52:149-56.
92. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 2004;490:187-97.
93. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003;19:232-40.
94. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes - Reduced awakening from sleep during hypoglycemia. Diabetes 2003;52:1195-203.
95. Chen M, Daly M, Williams N, Williams S, Williams C, Williams G. Non-invasive detection of hypoglycaemia using a novel, fully biocompatible and patient friendly alarm system. BMJ 2000;321:565-6.
96. Stocks AE. Can dogs help patients with hypoglycaemia? Diabetologia 2002;45:A79.
97. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683-9.
98. Dagogo Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in JDDM. Diabetes 1994;43:1426-34.
99. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long- duration insulin-dependent diabetes. Lancet 1994;344:283-7.
100. Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001;134:729-36.
101. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*. Diabetologia 2002;45:937-48.
102. Jorgensen HV, Pedersen-Bjergaard U, Rasmussen AK, Borch-Johnsen K. The impact of severe hypoglycemia and impaired awareness of hypoglycemia on relatives of patients with type 1 diabetes. Diabetes Care 2003;26:1106-9.
103. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997;19:62-72,
104. Brunelle BL, Llewelyn J, Anderson JH, Jr., Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-31.
105. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-70.
106. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77.
107. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541-77, discussion.
108. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-43.
109. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.
110. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301.
111. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.
112. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996;19:324-7.
113. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002;19:746-51.
114. Kanc K, Janssen MM, Keulen ET, et al. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia 1998;41:322-9.
115. Wiethop BV, Cryer PE. Alanine and terbutaline in treatment of hypoglycemia in IDDM. Diabetes Care 1993;16:1131-6.
116. Saleh TY, Cryer PE. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997;20:1231-6.
117. Porcellati F, Pampanelli S, Rossetti P, et al. Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans. Diabetes 2003;52:2774-83
118. De Galan BE, de Mol P, Wennekes L, Schouwenberg BJ, Smits P. Preserved sensitivity to beta2-adrenergic receptor agonists in patients with type 1 diabetes mellitus and hypoglycemia unawareness. J Clin Endocrinol Metab 2006;91:2878-81.
119. Hvidberg A, Rasmussen MH, Christensen NJ, Hilsted J. Theophylline enhances glucose recovery after hypoglycemia in healthy man and in type I diabetic patients. Metabolism 1994;43:776-81.
120. Watson JM, Sherwin RS, Deary IJ, Scott L, Kerr D. Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use. Clin Sci (Lond) 2003;104:447-54.
121. De Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002;51:790-6.
122. De Galan BE, Tack CJ, Lenders JW, Lutterman JA, Smits P. Effect of 2 weeks of theophylline on glucose counterregulation in patients with type 1 diabetes and unawareness of hypoglycemia. Clin Pharmacol Ther 2003;74:77-84.
123. Watson JM, Jenkins EJ, Hamilton P, Lunt MJ, Kerr D. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000;23:455-9.
124. Bingham E, Hopkins D, Pernet A, Reid H, MacDonald IA, Amiel SA. The effects of KATP channel modulators on counterregulatory responses and cognitive function during acute controlled hypoglycaemia in healthy men: a pilot study. Diabet Med 2003;20:231-7.
125. Gabriely I, Hawkins M, Vilcu, C, Rossetti L, Shamoon H. Fructose amplifies counterregulatory responses to hypoglycemia in humans. Diabetes 2002;51:893-900.
126. Gabriely I, Shamoon H. Fructose normalizes specific counterregulatory responses to hypoglycemia in patients with type 1 diabetes. Diabetes 2005;54:609-16.
127. Cox DJ, Clarke WL, Gonder-Frederick L, et al. Accuracy of perceiving blood glucose in IDDM. Diabetes Care 1985;8:529-36.
128. Cox DJ, Gonder Frederick LA, Lee JH, Julian DM, Carter WR, Clarke WL. Effects and correlates of blood glucose awareness training among patients with IDDM. Diabetes Care 1989;12:313-8.
129. Cox DJ, Gonder Frederick L, Julian DM, Clarke W. Long-term follow-up evaluation of blood glucose awareness training. Diabetes Care 1994;17:1-5.
130. Kinsley BT, Weinger K, Bajaj M, et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999;22:1022-8.
131. Ter Braak EW, de Valk HW, de la Bije YF, van der Laak MF, van Haeften TW, Erkelens DW. Response to training in blood glucose awareness is related to absence of previous hypoglycemic coma. Diabetes Care 2000;23:1199-200.
132. Broers S, le Cessie S, van Vliet KP, Spinhoven P, van der Ven NC, Radder JK. Blood Glucose Awareness Training in Dutch Type 1 diabetes patients. Short-term evaluation of individual and group training. Diabet Med 2002;19:157-61.